What You See Is Not Always What You Get


By Catherine Varmazis

Microarray gene expression studies are mainly used in two types of experiments: static and time-series. In fact, in the public domain, time-series experiments account for about 40 percent of the datasets. While time-series experiments are widely used to study biological systems, determining the quality of the results can be a fundamental problem according to Ziv Bar-Joseph, assistant professor of computer science and biological sciences at Carnegie Mellon University. Bar-Joseph is the inventor of a computational method that identifies genes missed by current analysis methods.


Some of the problems involved in the analysis of microarray data include determining the number of replicates for each time point, normalizing across different microarray platforms, and dealing with noise artifacts.


"Even if all these artifacts and noise are perfectly corrected, the resulting time-series profile may not really represent the underlying expression profile," says Bar-Joseph.

Why? One major issue is the sampling rate. In time-series experiments, measurements are taken at different intervals. "If a gene goes up and down in between these intervals, it can be missed even if everything is normalized. You might miss a collection of genes involved in some physiological process or drug response. This is a major issue. This is an error that cannot be caught now even with the most sophisticated normalization tools," says Bar-Joseph.


In addition, different arrest methods used to synchronize cells can cause many genes that are not involved in the system under investigation to react in response to the arrest-and-release treatments. This makes it hard to distinguish between expression profiles that are the result of genes participating in the system and changes stemming from the treatment itself. "The measurements are real in the sense that the genes are going up, but not as a result of the process you're studying, but rather because of the treatment," says Bar-Joseph.


The method Bar-Joseph pioneered aims to solve these problems and see if 'what you see is what you get.' Is what you observe in an expression profile really the way the gene operates in the system?

.

The experimental protocol involves only one additional microarray experiment in which a mixture of cells is profiled throughout the process. The averages/values obtained from this experiment are compared with the time-series profiles. If they agree, one can claim that what you see is what you get. If the time-series profile is higher than the average, one can conclude that the experiment results are a reaction to the treatment or something else unrelated to the process. If the average is high, but the time-series is low, then one can say you missed that gene, perhaps due to sampling problems.


"We did follow-up experiments and chose genes that could not have been identified based on time-series experiments alone, and the method picked them up correctly," says Bar-Joseph.


The program can be downloaded for free at:

http://www.cs.cmu.edu/~zivbj/checksum/checksum.html



Click here to login and leave a comment.  

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

White Papers & Special Reports

thomson reuters image
Biomarkers: An Indispensible Addition to the Drug Development Toolkit
Examining the Potential of Biomarkers
Sponsored by Thomson Reuters

Biomarkers are becoming an essential part of clinical development. In this white paper, Thomson Reuters provides insight from experts in industry and academia, and explores the role of biomarkers as evaluative tools in improving clinical research and the challenges this presents.

Discover the potential of biomarkers to:

  • Improve decision making
  • Accelerate drug development
  • Reduce development costs


BlueArc_Scientific Data
Scientific Data Lifecycle Management: Preparing for Storage in an Uncertain Future
Sponsored by BlueArc

Managing vast and overwhelming streams of gene sequencing data today requires ultra-high performance systems and processes. With continued rapid advancement and improvements in gene sequencing, expect tomorrow’s instruments to output quantities of genomic information that will dwarf current levels. Help your organization maintain data control and prepare for the future of sequencing through this informative paper that discusses:

  • The information technology challenges of gene sequencing
  • “Intelligent” methods for data management and customization
  • System survival tips... Deciding what data to keep or delete
  • New tools to keep scientists ahead of impending data torrents


SAS Managed image
Managed Innovation, Assured Compliance
Developing, executing and managing the transformation, analysis and submission of clinical research data with SAS® Drug Development
Sponsored by SAS
Get better products to market faster. Download this white paper to discover the top ten challenges facing life science executives and how to overcome them. See how SAS Drug Development transforms clinical data into true innovation.


Life Science Webcasts & Podcasts

Presented by Trade Commission of Spain

Spain Biotech: An Engine for Economic Change 

TCS podcastDiscover how Spain is focusing on biotechnology to be an engine for economic change through gradual internationalization, development and technology transfer.

Regional governments are actively investing in public and private biology research and promoting the creation of knowledge-based companies. Spain’s human capital combined with aggressive investment in biotech research and infrastructure has led to the creation of bio-clusters.

Today, there are nearly 700 Spanish companies engaged in biotechnology, with almost 50 percent growth in funding devoted to research. In fact, spending on internal R & D in biotechnology has grown 46 percent and is close to 300 million Euros.

Access the podcast 

 



More Podcasts

Job Openings

saic_logo

MANAGER, SCIENTIFIC COMPUTING & PROGRAMMING
(Bioinformatics Manager)
SAIC-Frederick, Inc has an exciting opportunity for a Manager, Scientific Computing & Programming - Core Genoytyping Facility in Gaithersburg, Maryland.  In this role, you will lead the Bioinformatics & Analysis Group.
Master’s or equivalent required.  PhD preferred. Six years experience in development of scientific programs in high-performance computing environment including five years supporting scientific research in computational chemistry, biology, or genetics, & two years supervisory experience.  View complete job posting & apply: www.saic-frederick.com. Position #146945.

For reprints and/or copyright permission, please contact The YGS Group, 1808 Colonial Village Lane, Lancaster, PA;

(717) 399-1900 ext. 125, or via email to Ashley.Zander@theYGSgroup.com.